Roivant Sciences

Vivek Ramaswamy founded Roivant Sciences in 2014. Focused on aligning incentives and improving capital efficiency, Ramaswamy's initial strategy was to in-license drug candidates and create subsidiaries focused on distinct therapeutic areas. This strategy expanded to include developing earlier stage drug candidates and platform technologies. Roivant is a parent company to over a dozen subsidiaries ranging from Immunovant, a majority-owned public company focused on autoimmune diseases, to privately held Dermavant Sciences, focused on medical dermatology.Roivant also develops healthcare technologies through investments in Datavant, which helps healthcare institutions safely share data, and Lokavant, which integrates clinical trial data to identify and mitigate risks in pharmaceutical development. As of 2019, Roivant had over 40 investigational drugs in development in 14 therapeutic areas across its family of companies.

The company's leadership includes: Mayukh Sukhatme, Matthew Gline, Eric Venker, Rakhi Kumar, and Ben Zimmer. As of 2017, Roivant was valued at $7 billion.At the end of 2019, Roivant formed a $3 billion partnership with Sumitomo Dainippon Pharma and transferred its ownership stake in five of its subsidiaries: Myovant Sciences, Urovant Sciences, Enzyvant Therapeutics, Altavant Sciences, and Spirovant Sciences, which now sit under Sumitovant Biopharma. The deal included the option for Sumitomo to acquire up to six additional subsidiaries.In April 2020, Roivant dosed the first patient in a clinical study evaluating gimsilumab in COVID-19 patients for the prevention and treatment of acute respiratory distress syndrome . Additionally, in April, Datavant Sciences announced that its technology is being used to create a pro bono COVID-19 research database to help public health and policy researchers combat the pandemic.In January 2021, Vivek Ramaswamy stepped down as CEO. Matt Gline, previously the company's chief financial officer, became CEO.In February 2021, Roivant Sciences acquired Silicon Therapeutics, a small-molecule drug designer and computational physics platform, for $450 million in Roivant equity.In October 2021, Roivant Sciences merged with special-purpose acquisition company Montes Archimedes Acquisition Corp. to become listed on the Nasdaq.Roivant Social Ventures is a 501 charitable organization that invests in health technologies and new therapeutics that lead to systemic improvements to health equity. Launched in 2020 by leaders from Roivant Sciences, RSV partners with innovative companies, institutes and organizations to promote systemic, sustained improvements to the way health care is accessed and delivered.